Waterfront Wealth Inc. Purchases Shares of 2,731 Biogen Inc. $BIIB

Waterfront Wealth Inc. purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,731 shares of the biotechnology company’s stock, valued at approximately $402,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Elevation Point Wealth Partners LLC acquired a new position in Biogen during the 2nd quarter worth $25,000. Rothschild Investment LLC raised its stake in shares of Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares in the last quarter. Concord Wealth Partners lifted its holdings in Biogen by 100.0% in the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 114 shares during the period. True Wealth Design LLC grew its position in Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 90 shares in the last quarter. Finally, NewSquare Capital LLC increased its stake in Biogen by 134.6% during the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 140 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Performance

Shares of BIIB opened at $193.81 on Tuesday. The company has a market capitalization of $28.43 billion, a PE ratio of 22.00, a PEG ratio of 1.70 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The company’s 50 day moving average price is $177.26 and its 200 day moving average price is $157.48. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $202.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts expect that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BIIB has been the topic of several recent analyst reports. BMO Capital Markets boosted their target price on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a report on Friday. Canaccord Genuity Group raised their price objective on Biogen from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen lowered shares of Biogen from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. HSBC reiterated a “reduce” rating and issued a $143.00 target price (down from $144.00) on shares of Biogen in a report on Wednesday, December 10th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Thirteen analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $206.21.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

Insider Activity

In related news, insider Priya Singhal sold 748 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the sale, the insider directly owned 6,271 shares in the company, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.18% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.